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a b s t r a c t
Inﬂuenza H9N2 is considered to be a low pathogenicity avian inﬂuenza (LPAI) virus that commonly
infects avian species and can also infect humans. In 1996, the inﬂuenza virus, A/chicken/Korea/MS96-
CE6/1996/H9N2 (MS96) was isolated from an outbreak in multiple farms in South Korea that resulted in
upwards of 30% mortality in infected chickens, with the virus infecting a number of extrapulmonary
tissues, indicating internal spread. However, in experimental infections, complete recovery of speciﬁc
pathogen free (SPF) chickens occurred. Such a discrepancy indicated an alternative pathway for MS96
virus to gain virulence in farmed chickens. A key determinant of inﬂuenza pathogenesis is the
susceptibility of the viral hemagglutinin (HA) to proteolytic cleavage/activation. Here, we identiﬁed
that an amino acid substitution, Ser to Tyr found at the P2 position of the MS96 HA cleavage site
optimizes cleavage by the protease plasmin (Pm). Importantly, we identiﬁed that certain Staphylococcus
sp. are able to cleave and activate MS96 HA by activating plasminogen (Plg) to plasmin by use of a
virulence factor, staphylokinase. Overall, these studies provide an in-vitro mechanism for bacterially
mediated enhancement of inﬂuenza activation, and allow insight into the microbiological mechanisms
underlying the avian inﬂuenza H9N2 outbreak in Korea in1996.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Each year, inﬂuenza-related illnesses cause 250,000–500,000
deaths in humans and economical loss equivalent to 27–87 billion
US dollars (World-Health-Organization, 2009b). In rare situations,
two or more inﬂuenza viruses exchange their RNA genomes by
antigenic switching and lead to emergence of novel pandemic
inﬂuenza viruses (Palese and Shaw, 2013). For instance, the 2009
pandemic virus arose from quadruple reassortment between birds,
pigs and humans inﬂuenza viruses (Smith et al., 2009; World-
Health-Organization, 2009a). Zoonotic transmission of animal
inﬂuenza to humans is also an important public health concern
(Butt et al., 2005; Lin et al., 2000). Avian inﬂuenza virus (AIV) is of
particular concern for such zoonotic transmission as practices in
the poultry industry provide an efﬁcient means of close contact
between humans and animals. Indeed, increasing cases of humans
infected by AIV have been reported, including transmission of both
highly pathogenic avian inﬂuenza (HPAI) H5N1 and avian inﬂu-
enza H9N2 and H7N9 (Butt et al., 2005; Peiris et al., 1999;
Watanabe et al., 2014). Furthermore, AIVs were involved in three
out of four pandemic inﬂuenza outbreaks from the last century,
indicating the tight link between pandemics in humans and avian
inﬂuenza viruses (Wright et al., 2013).
Inﬂuenza viruses have two surface glycoproteins, hemaggluti-
nin (HA) and neuraminidase (NA). HA binds to the cell receptor via
sialic acid residues on the surface of host cells and also mediates
membrane fusion (Skehel and Wiley, 2000). NA is a receptor-
destroying enzyme (a sialidase) that binds and cleaves sialic acid
on the cell surface, allowing efﬁcient egress of virus particles
(Mitnaul et al., 2000). Inﬂuenza virus requires activation before
infection, and activation efﬁciency is an important determinant of
viral virulence (Bosch et al., 1981; Chen et al., 1998; Klenk et al.,
1975). The process of virus activation involves proteolytic cleavage
of HA. After cleavage, the precursor protein HA0 is separated into
HA1 and HA2, which is required for successful viral entry. After the
virus binds to the host surface, it is internalized by receptor-
mediated endocytosis and deposited into the endosomal compart-
ment (Skehel and Wiley, 2000). During endosomal maturation, the
pH drops inside the endosomal lumen, which triggers HA to
undergo conformational changes (Bullough et al., 1994). The fusion
peptide in HA2 extends out and inserts into the endosomal
membrane, the endosomal and viral membranes merge and allow
pore formation to release the viral ribonucleoproteins (vRNPs) into
cytoplasm. The strict requirement of HA cleavage restricts
inﬂuenza infection to the upper respiratory tract of humans and
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2015.03.023
0042-6822/& 2015 Elsevier Inc. All rights reserved.
n Corresponding author at: Department of Microbiology and Immunology,
College of Veterinary Medicine, Cornell University, C4127 VMC Ithaca NY 14853,
USA. Tel.: þ1 607 253 4019; fax: þ1 607 253 3385.
E-mail address: grw7@cornell.edu (G.R. Whittaker).
Virology 482 (2015) 1–8
chickens, as well as the intestinal tracts of waterfowl, where
speciﬁc proteases for HA activation are available (Garten and
Klenk, 1999; Klenk and Garten, 1994). Overall, protease usage for
HA activation can be an important determinant of inﬂuenza
tropism (Bottcher-Friebertshauser, Klenk, and Garten, 2013).
Multiple proteases, mainly trypsin-like serine proteases, have
been shown to activate inﬂuenza HA (Garten and Klenk, 1999).
However, some of these proteases (e.g. plasmin) are not consid-
ered to be relevant under physiological conditions, either because
they are expressed in a different location that is not normally
infected by inﬂuenza, or the expression level is too low to activate
HA efﬁciently. The discovery of TMPRSS2 was a breakthrough for
studies on HA activation, as the expression pattern in the respira-
tory tract matches the site of inﬂuenza infection and TMPRSS2 was
shown to activate HA efﬁciently (Bertram et al., 2012; Bottcher
et al., 2006; Galloway et al., 2012). As shown in a TMPRSS2
knockout mouse model, TMPRSS2-deﬁcient mice showed partial
resistance to H1N1, H3N2 and H7N9 inﬂuenza viruses infection
compared to WT mice, supporting an important role of TMPRSS2
in inﬂuenza life cycle (Hatesuer et al., 2013; Sakai et al., 2014;
Tarnow et al., 2014). Other relevant proteases in the respiratory
tract include HAT, other TMPRSS family members, matriptase, and
KLK5/12 (Bottcher et al., 2006; Hamilton et al., 2013; Hamilton and
Whittaker, 2013; Ohler and Becker-Pauly, 2012). Proteases recog-
nize speciﬁc amino acid sequences found within their substrates,
within the general residue designation: P6–P60. The cleavage site
or scissile bond is located between the residue positions P1 and
P10. For trypsin, a prototype serine endopeptidase that is typically
studied in the context of HA cleavage, the protease strongly prefers
to cleave at P1 arginine (R) or lysine (K) residues. Other ﬂanking
residues are in general non-discriminatory for trypsin, but mod-
iﬁcation of other residues can have a major impact on HA cleavage
activation by alternate proteases.
Proteases for HA activation are not limited to host cell pro-
teases, and bacterial proteases are also involved in this process
(Bottcher-Friebertshauser et al., 2013). For instance, Staphylococcus
sp. secrete a soluble protease that is able to activate HA
(Scheiblauer et al., 1992). Furthermore, indirect activation of
inﬂuenza HA by bacterial co-factors is also a possible way of HA
activation. Pseudomonas aeruginosa also indirectly activates HA by
activating host proteases (Scheiblauer et al., 1992). Bacterial
streptokinase a and staphylokinase are also able to activate
eukaryotic plasminogen into plasmin, which then has the poten-
tial for activating HA. In contrast to other plasminogen activators,
which proteolytically cleave plasminogen between Arg561 and
Val562 to separate the kringle and protease domains of plasmino-
gen, streptokinase and staphylokinase are soluble protein secreted
by bacteria, which bind to plasminogen and allostericlly open up
the protease domain for plasmin function (Davidson, 1960; Lijnen
et al., 1991; Reddy and Markus, 1972). Interestingly, streptokinase
and staphylokinase activities are species-speciﬁc, whereby strep-
tokinase can activate human, monkey and cat plasminogen, but
staphylokinase can activate human, guinea pig and rabbit plasmi-
nogen (Wulf and Mertz, 1969). To our knowledge; there are no
reports on activities of staphylokinase or streptokinase on avian
plasminogen.
The inﬂuenza A/chicken/Korea/MS96-CE6/1996 (H9N2) virus
(MS96) was ﬁrst isolated in poultry farms during an avian
inﬂuenza outbreak in South Korea in 1996 (Lee et al., 2000).
MS96 was able to spread into four local farms, infecting mainly the
pullets in these farms. Mortality of chickens infected with MS96 is
moderately high, with a rate of 30%. Clinical symptoms of MS96-
infected chickens include diarrhea, facial edema and drop in egg
production to 0% (Kim et al., 2006). Necropsy of dead chickens
revealed swollen kidney with urate deposits, and atrophic and
ruptured ova (Mo et al., 2003). The MS96 virus was found inside
lung, kidney and feces from infected chickens, an indication of
internal spread of the virus. However standard pathogenicity
testing of MS96 in 6 week-old speciﬁc-pathogen free (SPF) chick-
ens in a laboratory setting revealed no mortality, and MS96 was
hence characterized as an LPAI (Kim et al., 2006). The discrepancy
between farmed chickens and SPF chickens is unclear. Interplay
between inﬂuenza virus and co-infecting bacteria is often reﬂected
in the clinical outcome in humans, where patients who have a
secondary bacterial infection are at higher risk of developing more
complicated disease progression (Bottcher-Friebertshauser et al.,
2013); a similar situation is likely in poultry, although to our
knowledge no such studies have been carried out. In general, the
synergy between inﬂuenza and bacteria is only partially under-
stood. However multiple mechanisms have been suggested,
including immunomodulation of bacteria by inﬂuenza or vice
versa, inﬂuenza neuraminidase (NA) activities opening up cryptic
receptors that enhance bacterial attachment and bacterial pro-
teases that may be directly involved in activating inﬂuenza HA
(Braciale et al., 2012; Chertow and Memoli, 2013; McCullers and
Bartmess, 2003).
Here, we examine the HA cleavage properties of the LPAI A/
Korea/MS96-CE6/1996/H9N2 (MS96) and uncover a novel mec-
hanism which may explain the synergy between inﬂuenza virus
and bacteria. In this study, we focus on a Ser to Tyr mutation at the
P2 position which is predicted to generate a robust plasmin
cleavage site in the MS96 HA. This is an equivalent mutation to
that found in a mouse-adapted neurotropic inﬂuenza virus, A/
WSN/1933/H1N1 (WSN) (Sun et al., 2010). MS96 displayed efﬁ-
cient plasmin-mediated HA cleavage, however, different from
WSN (Goto and Kawaoka, 1998; Li et al., 1993), the activation
mechanism of MS96 HA was independent of viral neuraminidase.
We show that MS96 HA can be indirectly activated by bacterial
staphylokinase in the presence of chicken plasminogen. Such
interaction is species-speciﬁc; of the bacterial co-factors we have
tested, only staphylokinase from Staphylococcus sp., bacteria that
are highly prevalent in farmed poultry, is able to activate ch-
plasminogen.
Results
Variation of the P2 position of HA cleavage site in H9 HA
A multiple sequence alignment of all inﬂuenza H9 HA from the
NCBI database revealed a consensus HA cleavage site R-S-S-R of H9
HA. (Fig. 1A) The cleavage site sequence and the ﬁrst 22 amino
acids of the fusion peptide of several representative strains of
H9N2 viruses are shown in Fig. 1A. The cleavage site of H9 HA is
highly conserved, with the exception of the P2 and P4 positions,
which show variability as depicted by Weblogo (Fig. 1B). Viruses
containing a P2 substitution are summarized in Fig. 1C, where
glycine (Gly, G), aspartic acid (Asp, D) and asparagine (Asn, N) are
the most common amino acids that replace the consensus P2
serine. Three particularly interesting clades, chicken/Korea/MS96-
CE6/1996 (10 strains), chicken/Korea/GH2/2007 (1 strain) and
ostrich/South Africa/9508103/1995 (1 strain) have a equivalent
P2 serine to tyrosine mutation resembling the neuro-replicative
mouse-adapted strain A/WSN/1933, giving them a HA cleavage site
of R-S-Y-R, which is optimal for plasmin mediated cleavage
(Backes et al., 2000; Hervio et al., 2000).
Chicken plasmin-mediated cleavage of MS96 HA
To determine whether the MS96 HA tyrosine mutation opti-
mizes HA for plasmin cleavability, MS96 HA was cloned into a
mammalian expression vector and a mutant with a single
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substitution at the P2 position back to consensus serine was
constructed. Cells expressing MS96 HA or MS96 HA-337S mutant
were treated with ch-plasmin (100 mU/ml) for increasing duration
(Materials and Methods). Cell surface HA was detected by biotiny-
lation and western blot. Western blot analysis reveals that MS96
HA is efﬁciently cleaved in a time dependent manner by ch-
plasmin. After 60 min of treatment with ch-plasmin, about 15% of
MS96HAWT is cleaved. In contrast, MS96 HA-337S does not show
any signiﬁcant cleavage with the highest being 5% after 60 min of
ch-plasmin treatment (Fig. 2a and b). However, when an increas-
ing concentration of ch-Pm is added, cleavage efﬁciency increases
and reaches saturation at an early time point MS96 HA cleavage by
trypsin (3 μg/ml) is decreased from 50% to 40% compared to MS96
HA-337S indicating that a tyrosine residue at position 337Y selects
for an alternative protease and slightly comprises the use of
original protease for activation (Fig. 4a and b).
Plasminogen-mediated cleavage of MS96HA requires a plasminogen
activator independent of MS96 NA
A hallmark of the WSN virus is the additional NA-N146R
mutation on the viral neuraminidase, which destroys a glycosyla-
tion site and allows plasminogen recruitment to the viral surface.
The recruited plasminogen is then activated into plasmin and
subsequently cleaves HA by an unknown mechanism that is likely
to involve tissue plasminogen activator (tPA) on the cell surface
(Goto and Kawaoka, 1998; Lazarowitz et al., 1973). To determine
whether MS96 NA performs a similar function as WSN NA in
recruiting plasminogen and activating its cognate HA, cells expres-
sing MS96 HA along with either MS96 NA or WSN NAwere treated
with ch-plasminogen (5 μg/ml) for 18 h. Biotinylation and western
blot analysis shows HA cleavage of MS96HA WT only in the
presence of WSN NA with about 40% of HA cleavage (Fig. 3). This
result suggests both a P2 tyrosine and a plasminogen recruiter are
required for HA activation, which is independent of MS96 NA.
The bacterial co-factor staphylokinase indirectly cleaves MS96HA
In search of a plasminogen recruiter and activator for MS96 HA,
we hypothesized that an alternative source of activated plasmino-
gen could be produced from co-infecting bacteria, principally
staphylokinase from Staphylococcus sp. Both WT and mutant
MS96 HAwere transfected into 293T cells for surface biotinylation.
Ch-plasminogen (5 μg/ml) was incubated with staphylokinase
(10 μg/ml) for 1 h at 37 1C for activation prior to treatment.
Transfected cells underwent different treatments as indicated.
Western blot analysis reveals HA cleavage of 35% when MS96
HA is incubated with both ch-plasminogen and staphylokinase
(Fig. 4). No signiﬁcant HA cleavage was detected from any other
treatment. Another known bacterial plasminogen activator, strep-
tokinase C (skc) from Streptococcus zooepidemicus (a bacterium
also commonly present in farmed chickens) showed only very
weak activity on ch-plasminogen mediated HA cleavage (data
not shown)
Ch-plasmin and plasminogen mediated HA cleavage is functional and
activates the virus
From western blot analysis, it is clear that MS96 HA is cleaved
by ch-plasmin. Nevertheless, a functional assay was needed to
conﬁrm that the cleavage is at the correct position and would
activate the virus. We used a surrogate pseudovirus system from
mouse leukemia virus (MLV) to produce inﬂuenza pseudoviral
particles (PV). MS96 HA, NA along with MLV-Gag-pol, pTG-Luc are
co-transfected into 293T cells for 48 h (see Materials and Methods).
The harvested PVs were treated differently as indicated and the
treated PVs were used to infect MDCK cells. Luciferase activities
were assayed after 2 days post-transduction by lysing the MDCK
cells with cell lysis buffer. PVs infection is measured by reading of
luciferase activities monitoring as an indirect method to assay
functional HA activation. The data agree with HA cleavage results
Fig. 1. Bioinformatic analysis of inﬂuenza H9N2 HA cleavage site. (A) Multiple sequence alignment of full length H9N2 HA from NCBI inﬂuenza database (http://www.ncbi.
nlm.nih.gov/genomes/FLU/FLU.html). A total of 3019 sequences were aligned by MUSCLE alignment program. HA Consensus sequence from the P6 residue of the cleavage site
through the ﬁrst 22 amino acids sequence of the fusion peptide are shown in bold. Representative strains are shown underneath the consensus whereas differences are
shown in single letter amino acid code. Accession numbers of the representative strains are as follows: A/duck/Hong Kong/W213/1997 (BAG72217), A/chicken/Hong Kong/
G9/1997 (AAF00701), A/turkey/Wisconsin/1/1966 (BAA14335), A/chicken/South Korea/MS96-CE6/1996 (ACZ48628), A/chicken/South Korea/GH2/2007 (ADV36582) and A/
ostrich/South Africa/9508103/1995 (AAQ04843). (B) Amino acids frequency at HA cleavage site. Frequencies of each position, from P6 to P3’ of the H9 HA cleavage site are
illustrated using WebLogo 3.4 (http://weblogo.threeplusone.com/). (C) Summary of P2 position variation of H9 HA. A numerical summary of the variation in the P2 position
from 3019H9N2 strains.
L.V. Tse, G.R. Whittaker / Virology 482 (2015) 1–8 3
by western blot analysis whereas PV is activated after incubation
with ch-plasminogen and staphylokinase (Fig. 5). HA cleavage is
also dependent on a P2 tyrosine as MS96 HA-337S PV did not
show signiﬁcant activation. We also tested another bacterial co-
factor streptokinase (streptokinase) and showed very little HA
cleavage or activation, suggesting a bacteria-speciﬁc HA activation
mechanism in MS96 virus (data not shown).
Staphylokinase is more efﬁcient than streptokinase in activating
ch-plasminogen
Several bacterial co-factors have shown some degree of species
speciﬁcity in activating plasminogen. We tested three different
bacterial plasminogen activators (staphylokinase, streptokinase a
from Streptococcus pyogenes and streptokinase b from group B
streptococcus III) for their activity on ch-plasminogen using a
ﬂuorogenic peptide assay. Brieﬂy, the ﬂuorogenic peptide, which
mimics the consensus sequence of H1N1 inﬂuenza HA (MCA-
H1N1HA-DNP) and plasminogen are mixed with different recom-
binant bacterial plasminogen activators. The assay serves as an
indirect measurement of plasminogen activation as only activated
plasminogen can cleave the ﬂuorogenic peptide, which then
releases the quenched ﬂuorescence pair emitting a signal. In
Fig. 2. Chicken plasmin mediated A/Chicken/MS96-CE6/19966 (MS96) HA cleavage
is dependent on 337Y. (A) HA cleavage of MS96 HA and MS96 HA-337S by ch-
plasmin. Surface biotinylation was performed on 293T cells expressing each HA.
Transfected cells were treated with ch-plasmin (100 mU/ml) at the indicated time
and cleavage product(s) were detected by western blot using anti-C9 antibody.
(B) Quantiﬁcation of the time-dependent ch-plasmin mediated HA cleavage
efﬁciency MS96 HA and MS96 HA-337S. The error bars represent the standard
deviation of three independent experiments. Statistics were performed using a
Student's t-test (unpaired, one-tail) in GraphPad Prism, comparing each individual
treatment time (npo0.05, nnpo0.005, nnnpo0.0001).
Fig. 3. HA cleavage of MS96 HA by chicken plasminogen (ch-plasminogen)
independent from its cognate neuraminidase. (A) Representative western blot
picture of surface biotinylation after co-transfecting MS96 HA with MS96 NA or
WSN NA in the presence or absence of ch-plasminogen (5 μg/ml) for 18 h.
Fig. 4. Staphylokinase (sak) from Streptococcus aureus allows chicken-plasminogen (ch-
Plg) mediated HA cleavage of MS96 HA. (A) Surface biotinylation was performed as
mentioned above. 293T cells were transfected with MS96 HA and MS96 HA-337S and
treated with different proteases as indicated for 1 h. Cleavage products were detected by
western blot using anti C9 antibody. (B) Quantiﬁcation of the staphylokinase/plasmino-
gen (sak-Plg)-dependent HA cleavage efﬁciency. Cleavage efﬁciencies were calculated.
The error bars represent the standard deviation of three independent experiments, and
statistics were performed as in Fig. 2.
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agreement with the biotinylation and PV assay, staphylokinase is
able to activate both ch-plasminogen and h-plasminogen (Fig. 6a).
Another co-factor, streptokinase a only activates h-plasminogen
but not ch-plasminogen under the same experimental conditions
(Fig. 6b). However, streptokinase b, which has been shown to have
no activity in plasminogen activation (Wiles et al., 2010) is unable
to activate either h-plasminogen or ch-plasminogen as expected
(Fig. 6c). The kinetic parameters of this experiment represent the
combination of plaminogen activation and hydrolysis of the
peptide. Since the intrinsic activity of h-plasminogen and ch-
plasminogen to the ﬂuorogenic peptide is different, it is unable
to deduce the accurate rate of plasminogen activation with
this assay.
Discussion
Using multiple sequence alignment of all the avian H9N2
viruses from the inﬂuenza database, we identiﬁed a group of LPAI
viruses that have the same serine to tyrosine mutation at the P2
position of HA cleavage site as the neurotropic inﬂuenza WSN.
Although the P2 and P4 positions of H9N2 HA cleavage site are
relatively more dynamic than other positions at the cleavage site,
the reoccurrence of the P2 tyrosine mutation multiple times in
Asia cannot be simply explained by stochastic mutation of an RNA
virus. Our data suggest that the P2 tyrosine mutation allow the
virus to use an alternative protease, ch-plasmin, for HA activation.
Although ch-plasmin is very abundant, with the concentration
of 2 μM in the circulation system, it is under very tight regulation
– as are most proteases in vivo (Cederholm-Williams, 1981).
Plasmin activity depends on different plasminogen activators to
process plasminogen into the active form of plasmin (Irigoyen et
al., 1999; Nienaber et al., 1992). The WSN virus uses its cognate NA
to recruit plasminogen to the cell surface, to be activated by cell
surface bound t-PA and hence HA activation. Instead of using the
same NA-dependent mechanism, the MS96 virus has a completely
different mechanism for HA activation. MS96 HA uses a bacterial
plasminogen activator, staphylokinase from Staphylococcus sp. to
activate ch-plasminogen to ch-plasmin and allow HA activation.
Interestingly, not all the bacterial plasminogen activators show
similar activities on ch-plasminogen. Using a biochemical assay
with ﬂuorogenic peptides, we tested two other bacterial plasmi-
nogen activators, streptokinase a and b, and showed that both of
them do not have the same effect on ch-plasminogen compared to
staphylokinase.
In an attempt to test the actual MS96 virus using ch-plasmin for
activation, we ampliﬁed the MS96ce6 virus (obtained from St. Jude
Children's Hospital) in both embryonic egg and MDCK cells.
Unfortunately, the MS96 virus failed to grow to high titer
(103 pfu/ml) after 3 passages in both systems, which suggested
extensive adaptation is required. Instead of undertaking extensive
adaptation, with the risk of introducing additional mutations into
MS96, we used a surrogate pseudovirus system to test the
activation of MS96 HA. Results from the pseudovirus (PV) assay
agree with the western blot ﬁndings, showing that MS96 PV is
activated by ch-plasmin and also by the combination of staphylo-
kinase and ch-plasminogen, while the isogenic serine revertant
337S showed a sub-optimal activation.
In most cases, inﬂuenza viruses overcome the tropism restric-
tions by mutating the HA cleavage site to utilize other unconven-
tional proteases for activation without interacting with other
pathogens (Orlich et al., 1995; Orlich and Rott, 1994). For instance,
Fig. 6. Species speciﬁcity of bacterial plasminogen activator in activating plasmi-
nogen. Indirect measurement of the activities of different bacterial plasminogen
activators a) staphylokinase (sak), b) streptokinase a (ska) and C) streptokinase b
(skb) towards chicken (ch-Plg) and human plasminogen (h-pPlg). The kinetics of
cleavage of the ﬂuorogenic peptide is measured by the relative ﬂuorescence units
over time. H-plasminogen, ch-plasminogen and bacterial plasminogen activator
alone is acted as negative controls for all three experiments.
Fig. 5. Luciferase-based pseudoviral particles (PV) assay of MS96 HA and MS96 HA-
337S produced in 293T cells. Quantitative HA mediated PV transduction assay in
MDCK cells. Murine leukemia virus (MLV) based PV with HA and NA on the surface
were produced in 293T cells described in Material and Methods (chicken (ch),
plasmin (Pm) plasminogen (Plg) staphylokinase (Sak). Harvested supernatant were
underwent different treatments (trypsin 3 μg/ml ch-Pm 5 μg/ml, ch-Plg 5 μg/ml,
Sak 10 μg/ml) before infecting MDCK cells. Infections were done in duplicates on
MDCK cells for 2 days. Cells were lysed and relative light units (RLUs) were
measured after addition of luciferin. Error bars represent 1S.D. of 3 independent
experiments.
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WSN, the neurovirulent mouse-adapted strain of inﬂuenza, gains
its tropism in brain tissue by alteration of HA cleavability by using
plasmin (Sun et al., 2010). Furthermore, highly pathogenic avian
inﬂuenza (HPAI) is able to replicate systemically in animals by
acquiring mutations at the cleavage site which allow a ubiquitous
protease (furin) for activation (Kawaoka and Webster, 1988).
Recently, we identiﬁed a single mutation of serine to lysine at
the P2 position of H9N2 cleavage site allow minimal furin activa-
tion of the virus (Tse et al., 2014). In this study, we show a
mutation at the same P2 position from Ser to Tyr could also
increase the HA cleavability by interacting with other bacterial co-
factor to set up a unique activation mechanism.
Ideally, challenge experiments in chickens need to be per-
formed to consolidate the hypothesis of the inﬂuenza-bacteria
synergism via interaction between viral HA, bacterial staphyloki-
nase and ch-plasminogen. These experiments would also allow us
to determine the in-vivo phenotype of virus inside of infected
chicken and determining whether viruses can disseminate
throughout the body with the help of bacteria, as seen in other
H9N2 viruses with a nephrotropic phenotype (Hadipour et al.,
2011; Mosleh et al., 2009; Pazani et al., 2008). Co-inoculation of
MS96 and Staphylococcus aureus with an isogenic control of
Staphylococcus aureus Δstaphylokinase in chicken could also be
performed. Such experiments would require a BSL-3 avian facility
under close supervision by biosafety authorities.
Conclusions
Together, our ﬁndings highlighted the importance of S337Y muta-
tion in MS96 cleavage site modulates HA activation in-vitro by plasmin
and provided a potential mechanism for indirect HA activation by
bacterial staphylokinase. However, similar to all retrospective studies,
our in-vitro data provide a possible explanation of the unusual high
mortality rate in the MS96 outbreak in 1996, but do not reﬂect the
actual incidence in the ﬁeld. Considering such limitations, the indirect
activation of HA by bacterial plasminogen activators described here
has been demonstrated by our previous ﬁndings, where a human
pandemic inﬂuenza virus used bacterial streptokinase to enhance
virulence and providing supportive evidence for the feasibility of our
mechanism (Tse et al., 2013).
Material and methods
Cells, viruses, plasmids and reagents
293T/17 (CRL-11268) and MDCK (CCL-34) cells (American Type
Culture Collection, ATCC) were maintained in Dulbecco's modiﬁed
Eagle's medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (Gibco), 100 units/ml of penicillin and 10 μg/ml
of streptomycin (Cellgro), and 25 mM HEPES (Cellgro) at 37 1C in a
5% CO2 incubator. The MS96 HA gene (accession# AAF69255) and
the MS96 NA gene (accession#AZC45243) were synthesized by
Gene Art. WSN NA has been previously described (Sun et al., 2010).
The HA gene was sub-cloned into the pEF4 vector (Invitrogen)
which has the addition of C9-tag at the C-terminus. NA genes were
sub-cloned into the pCAGGS vector. Point mutations were intro-
duced by QuickChange site-directed mutagenesis kit (Aglient)
following the manufacturer guideline. TPCK-trypsin was obtained
from Themo Scientiﬁc; staphylokinase was obtained from BioVen-
dor Laboratory Medicine, Inc., chicken plasminogen (ch-plasmino-
gen) and chicken-plasmin (ch-plasmin) were obtained from
Innovative Research. Streptokinase and streptokinase b (skb) was
cloned from Streptococcus pyogenes NZ131 (ATCC BAA-1633) and
Streptococcus agalactiae (ATCC 12403) respectively, into ppSUMO
with a 6xHis-SUMO tag at the C-terminus.
Surface biotinylation and western blot
293T cells were grown on poly-D-lysine-treated 24 well plates
to 60–70% conﬂuence and transfected with 500 ng of plasmid
using Lipofectamine 2000 for 18 h. Transfected cells were washed
with PBS and underwent different treatments in DMEMþ0.2% BSA
as speciﬁed in each experiment. After the treatment, the plates
were kept at 4 1C on ice and were washed with PBS and incubated
with Sulfo-NHS-SS-biotin (250 μg/ml, Sigma) for 30 min. Excess
biotin was quenched with glycine (50 mM) for 10 min. Cells were
washed with PBS and then lysed by 1RIPA buffer (Millipore)
with Complete™ protease inhibitor cocktail tablets (Roche) for
10 min. Lysed cells were centrifuged at 18,000g for 20 min at 4 1C,
supernatant was collected and added to 30 μl of a 50% suspension
of streptavidin agarose beads (Thermo) and incubated at 4 1C on a
rotating shaker for 18 h to pull down all the biotinylated proteins.
The beads were washed 3 times with RIPA buffer and resuspended
in 30 μl of 2 Laemmli sample bufferþ10% beta-mercaptoethanol
for western blotting. HA bands were detected by primary mouse
α–C9 (ID4) antibody (Abcam) and secondary goat α-mouse con-
jugated to horseradish peroxidase (Thermo).
Quantiﬁcation of HA cleavage
Western blot images were taken using a FujiFilm LAS-3000
imager. The pixel intensity of individual band was determined
using Image J, and relative cleavage efﬁciencies were calculated by
the following equation:
½ HA2= HA0þHA2ð Þ
  100:
MLV-based inﬂuenza pseudoviral particles (PV) transduction assay
To produce MLV based PV, 293T cells were grown on 12 well
plates to 50–60% conﬂuence and transfected with MLV-gag-pol
(350 ng), pTG-luc (500 ng), A/chicken/Korea/MS96/1996 (H9N2)
NA (350 ng), HA (350 ng) and furin plasmids (350 ng, speciﬁed in
individual experiment) for 48 h using Lipofectamine 2000. Super-
natants were harvested and ﬁltered through a 0.45 mm ﬁlter to
remove any cell debris. The ﬁltered supernatants containing PV
were treated with or without trypsin (3 μg/ml) as speciﬁed in each
experiment for 15 min at 37 1C to allow HA activation. After
activation, excess trypsin activity was neutralized by addition of
a 1:1 ratio of complete DMEM containing trypsin inhibitor from
Glycine max (soybean) (Sigma-Aldrich). MDCK cells were grown on
24 well plates to 60–70% conﬂuence and infected in duplicate by
200 μl of PV-complete DMEM mixture for 1 h. 500 ml of
DMEMþ2%FBSþHepesþP/S was added to each well and incu-
bated for 48 h for transduction. Cells were lysed by 1 cell culture
lysis reagent (Promega) for 1 h at room temperature on a rocker.
Transduction efﬁciency is measured as RLUs using a GloMax-20/20
luminometer (Promega) by mixing 10 μl of lysate and 20 μl of
luciferase assay reagent (Promega).
Ch-plasminogen activation by staphylokinase
Staphylokinase (100 μg/ml) and ch-plasminogen (50 μg/ml)
were pre-incubated in 20 mM Tris pH 7.5 for 1 h at 37 1C before
treatment and use as a 10 solution
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Protein puriﬁcation of recombinant bacterial plasminogen activators
100 ml of bacterial culture BL21-RIL was grown in LBþkana-
mycin to O.D600 0.8–1.0 and induced with IPTG (100 μM) at 16 1C
overnight. Bacterial pellet was harvested by centrifugation at
4.4 K rpm for 30 min. The bacteria were broken up by sonication
on ice and the supernatant was saved for protein puriﬁcation using
a Nickel-NTA column (1.5 ml bead volume) by gravitation ﬂow.
Recombinant protein was eluted in total of 3 ml of 20 mM Tris pH
7.5þ250 mM imidazole.
Fluorogenic peptide assay of bacterial plasminogen activator activity
Ch-plasminogen (50 μg/ml) or H-plasminogen (50 μg/ml)
is mixed with different bac-PA in a non-transparent 96-well plate
in 20 mM Tris pH 7.5 with total volume of 47 ul. The reaction mix
is incubated at 37 1C for 1 h followed by an addition of 3 μl of the
substrate (ﬁnal concentration 100 μM), ﬂuorogenic peptide
mimicking an inﬂuenza HA cleavage site (IPSIQSRGL) with the
ﬂuorescence resonance energy transfer pair 7-methoxycoumarin-
4-yl acetyl (MCA) and N-2,4-dinitrophenyl (DNP) on N and C
terminus respectively on ice. Kinetics of the reaction was mea-
sured every 1 min for 1 h with the excitation at 370 nm and
emission at 440 nm at 37 1C by SpectraMax GeminiXS (Molecular
Devices).
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